These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 32837113)

  • 41. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
    Dampalla CS; Miller MJ; Kim Y; Zabiegala A; Nguyen HN; Madden TK; Thurman HA; Machen AJ; Cooper A; Liu L; Battaile KP; Lovell S; Chang KO; Groutas WC
    Eur J Med Chem; 2023 Jun; 254():115376. PubMed ID: 37080108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation.
    Elekofehinti OO; Iwaloye O; Molehin OR; Famusiwa CD
    In Silico Pharmacol; 2021; 9(1):49. PubMed ID: 34395160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phytochemicals against SARS-CoV as potential drug leads.
    Swain SS; Panda SK; Luyten W
    Biomed J; 2021 Mar; 44(1):74-85. PubMed ID: 33736953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
    Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
    Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In silico screening of Allium cepa phytochemicals for their binding abilities to SARS and SARS-CoV-2 3C-like protease and COVID-19 human receptor ACE-2.
    Bondhon TA; Fatima A; Jannat K; Hasan A; Jahan R; Nissapatorn V; Wiart C; Pereira ML; Rahmatullah M
    Trop Biomed; 2021 Jun; 38(2):214-221. PubMed ID: 34172713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repurposing antiviral phytochemicals from the leaf extracts of Spondias mombin (Linn) towards the identification of potential SARSCOV-2 inhibitors.
    Boadu A; Agoni C; Karpoormath R; Soliman M; Nlooto M
    Sci Rep; 2022 Jun; 12(1):10896. PubMed ID: 35764663
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
    Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
    J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structural basis of SARS-CoV-2 3CL
    Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
    J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening.
    Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):1008-1016. PubMed ID: 33062953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
    Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
    Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. SARS-CoV-2 M
    Bharadwaj S; Azhar EI; Kamal MA; Bajrai LH; Dubey A; Jha K; Yadava U; Kang SG; Dwivedi VD
    J Biomol Struct Dyn; 2022 Apr; 40(6):2769-2784. PubMed ID: 33150855
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
    Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W
    bioRxiv; 2020 Aug; ():. PubMed ID: 32803196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.